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Abstract 
In this work novel injectable Calcium Phosphate Foams (CPFs) were combined with an 
antibiotic (Doxycycline) to design an innovative dosage form for bone regeneration. 
The material structure, its drug release profile and antibiotic activity were investigated, 
while its clinical applicability was assessed through cohesion and injectability tests. 
Doxycycline had a clear effect on both the micro- and macro- structure of the CPFs due 
to its role as nucleating agent of hydroxyapatite and a drying effect on the paste. 
Doxycycline-loaded CPFs presented interconnected macroporosity, which increased 
drug availability as compared to Calcium Phosphate Cements, and was a critical 
parameter controlling the release kinetics, which followed a non-Fickian diffusion 
model. Up to 55% (1 mg) of the drug was released progressively in 5 days, the 
percentage released being proportional to the macroporosity of the CPFs. All 
Doxycycline-containing foams had immediate cohesion and were injectable. Moreover, 
antibacterial activity was observed against Staphylococcus Aureus and Escherichia 
Coli. Thus, in addition to enhancing osteoconduction and material resorption, 
macroporosity allows tuning the local delivery of drugs from injectable calcium 
phosphates. 
 
Keywords:  calcium phosphate cement; foam; scaffold; drug delivery; controlled 
release; antibiotic 
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1. Introduction 
Calcium Phosphate Cements (CPCs) show numerous attractive features when 
used as synthetic bone grafts. Their ability to set in vivo into calcium-deficient 
hydroxyapatite grants an excellent compatibility with the damaged bone and the 
possibility to be progressively replaced by new bone over time [1]. In addition, their use 
as local drug delivery systems for many drugs, mainly antibiotics, anti-inflammatories, 
anti-cancer or anti-osteoporosis drugs, has been widely investigated [2–6]. 
However, CPCs lack interconnected macroporosity. This hinders cell 
colonisation, limits the possibility of circulation of nutrients and cell waste in the 
material, and impairs material resorption, thus preventing a quick bone ingrowth [7]. 
When used as drug delivery system, physiological fluids have reduced access to the 
center of the matrix, potentially leading to an incomplete release of the active principle 
[8], particularly in slowly-degradable CPCs, like apatite cements [1]. On top of limiting 
the efficacy of the treatment, this can increase the risk of generating antibiotic-
resistance [9]. Different methods can be used to overcome these limitations. 
Specifically, drug-loaded polymeric porogens have been combined with the CPCs with 
the purpose of generating macroporosity and releasing drugs in a controlled manner, as 
reviewed by Habraken et al. [10]. However, this method has also some drawbacks: 1) 
the macroporosity created by the porogen leaching is not available at early moments to 
allow blood clotting in the graft; 2) leaching of the porogen should not be detrimental to 
the regenerative process; 3) the proportion of porogen should be very high to generate 
an interconnected network of macropores; 4) the size of the porogen particles should be 
sufficient to generate macropores, and thus might be detrimental to injectability. The 
foaming approach used in this work presents an attractive, simple alternative to these 
drawbacks. Macroporous self-setting Calcium Phosphate Foams (CPFs) can be obtained 
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by foaming a surfactant-containing liquid and subsequently mixing with a reactive 
calcium phosphate powder [11–13]. This process generates an additional interconnected 
macroporosity to the already existing microporosity of CPCs, without losing 
injectability nor requiring a subsequent step of porogen elimination. Thus, 
macroporosity is available instantaneously to the release media/corporal fluids. 
Different additives have been studied to foam the liquid phase of CPCs: low molecular 
weight surfactants (Sorbitol, Tween80) [11] or proteins, like albumen [13] or gelatin 
[12]. The resulting foam, its stability and structure depend strongly on the chosen 
foaming agent, due to different mechanisms of action, such as the repulsive interactions 
between the adsorbed layers or the confinement of aggregates within the thin films [14].  
A number of antibiotics, like aminoglycosides (gentamicin), cephalosporins 
(cephalexin) and glycopeptides (vancomycin) have been proposed as active principles 
in combination with CPCs, in applications requiring both bone regeneration and local 
treatment of an infection. Although the local presence of the active principle enhances 
its efficacy, antibiotics can have side-effects. For instance, gentamicin is thought to 
affect cell viability, proliferation and metabolism; cephalosporins inhibit osteoblast cells 
function whereas vancomycin is less aggressive at low concentrations [15]. 
Interestingly, Kallala et al. claimed that tetracyclines present some beneficial effects 
when targeting bone regeneration [16] i.e. enhancement of bone mineralisation and 
induction of apoptosis of osteoclasts in vitro, thus limiting bone resorption [17]. The 
tetracycline employed in this work is Doxycycline Hyclate (Doxy). It has been used to 
treat a wide variety of infections including periodontitis [18], osteomyelitis [19–21] and 
Methicillin Resistant Staphylococcus Aureus (MRSA) [22]. Beneficial effects on bone 
metabolism have been reported for Doxy even at low concentrations, i.e. 2-5 μg/mL 
[15]. 
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In this work, for the first time, a new dosage form, intended for local treatment 
of infected bone defects, is proposed based on self-setting injectable CPFs in 
combination with an antibiotic. Different aspects are investigated, such as:  i) the 
influence of the incorporation of Doxy on the porosity, macroporosity and pore 
interconnectivity of CPFs;  ii) the effect of the structural properties of the foam on the in 
vitro drug release kinetics;  iii) the relevance of interconnected macroporosity on the 
release and antimicrobial activity of the antibiotic. 
2. Materials and Methods 
2.1. Liquid and solid phase preparation 
α-TCP was used as solid phase of the CPFs, and was obtained by heating in a 
furnace (CNR-58, Hobersal, Spain) in air a 2:1 molar mixture of calcium hydrogen 
phosphate (CaHPO4, Sigma Aldrich, USA) and calcium carbonate (CaCO3, Sigma-
Aldrich, USA) at 1400 ºC for 15 h followed by quenching in air. The α-TCP obtained 
was milled in an agate ball mill (Pulverisette 6, Fritsch GmbH, Germany) using 10 
agate balls (d=30 mm) for 15 min at 450 rpm. 2 wt% of precipitated hydroxyapatite 
(BP-E341, Merck, Germany) was added as a seed in the powder. The liquid phase was a 
solution of 1 wt% of Polysorbate 80, herein Tween80 (Polysorbate 80, Sigma Aldrich, 
USA) in distilled water. 
Doxycycline Hyclate (Doxy; Doxycycline hydrochloride hemiethanolate 
hemihydrate, Sigma-Aldrich, USA) in powder form was used as received. The 
schematic representation of the Doxy formula, i.e. C22H24N2O8 * HCl * 0.5H2O * 
0.5C2H6O, is show in Fig. 1. 
2.2. Preparation of calcium phosphate foams 
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Self-setting CPFs were prepared by foaming the liquid phase at 6000 rpm for 30 
s using a domestic hand mixer followed by hand mixing with the solid phase. The liquid 
to calcium phosphate powder ratio was maintained constant and equal to 0.55 mL/g, as 
in previous works [11]. The amount of Doxy blended with the powder phase was a 
multiple of the lowest dose (D) corresponding to 0.88 wt%. The different materials 
prepared, including the nomenclature used, amounts of liquid phase, calcium phosphate 
powder and antibiotic, and weight percentage of antibiotic in the material (Cdoxy) are 
reported in Table 1. 
 
CPFs were then cast manually into Teflon cylindrical moulds of 6 mm diameter 
and 12 mm height, and allowed to consolidate at 37 ºC and 100 % relative humidity for 
1 h before immersion in water for 7 days for further reaction before subsequent 
characterisation. 
2.3. Material characterisation 
The surface tension of different dissolutions of Doxy in 1 % of Tween 80 
aqueous solution was measured. The concentrations chosen correspond to the doses of 
Doxy of each formulation of CPFs assuming total dissolution in the liquid phase, 
namely 0, 25, 50, 75 and 100 mg/mL. A tensiometer (K100, Krüss, Germany) with a Pt 
plaque was used to evaluate the surface tension. 
The plastic limit of non-foamed CPC pastes containing different amounts of 
Doxy was evaluated via a simple technique, as described elsewhere [23]. Briefly, 1 g of 
powder phase was weighted and mixed with the adequate quantity of Doxy. 200 µL of 
distilled water were initially added to the powder phase and mixing was performed with 
a spatula until homogenisation. A drop of water was then added and mixed again until 
homogenisation. The process was repeated until the system had the consistence of a 
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paste, and thus the plastic limit was reached. The paste was then weighted and the liquid 
to powder ratio at the plastic limit was calculated.  
A cohesion test was performed according to the protocol described in Montufar 
et al. [12]. Briefly, calcium phosphate foams (0D-CPF, 1D-CPF, 2D-CPF, 3D-CPF, 4D-
CPF) were freshly prepared. After 2.5 min, a small amount of the foamed material was 
injected into a cylindrical cavity of 4 mm height and 8 mm diameter in a commercial 
polyurethane sponge immersed in water at 37 °C. The integrity of the paste was 
evaluated visually using an arbitrary scale from 1 to 4, 1 meaning no cohesion, i.e. paste 
disruption immediately after injection, and 4 meaning excellent cohesion, i.e. intact 
paste after injection and consolidated structure after 24 hours. 3 replicates were used for 
each composition. 
To assess the effect of the addition of Doxy on injectability, calcium phosphate 
foams were prepared and placed into a commercial syringe with a 2 mm aperture at the 
tip, a 13 mm cartridge and a nominal capacity of 5 mL. The injection test was 
performed using a universal testing machine (BIONIX, MTS, USA) 2.5 min after 
preparation of the foams. The injection was performed at 15 mm.min-1 until a force of 
100 N was achieved. The parameters measured were the injection force, defined as the 
mean value of the plateau force needed to inject the material, and the injectability, 
defined as the percentage of the material injected, evaluated by direct weighting of the 
paste [24]. 
X-ray diffraction analysis (XRD) of the foams after consolidation at 37 ºC and 
100 % relative humidity for 1h followed by immersion in water at 37 ºC for 7 days was 
performed using an X’Pert powder X-ray diffractometer (PANalytical, Netherlands) to 
evaluate phase composition. The XRD measurements were obtained by scanning in 
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Bragg–Brentano geometry using CuKα radiation. The experimental conditions were: 2θ 
scan step 0.017 between 20 and 70, counting time 50 s per step, voltage 45 kV and 
intensity 40 mA. The diffraction patterns were compared and phases quantified using 
the Joint Committee on Powder Diffraction Standards for α-TCP (JCPDS No. 00-029-
0359) and hydroxyapatite (HA) (JCPDS No. 01-082-1943), using the EVA software 
(Brucker, Germany). 
A Field Emission Scanning Electron Microscope (FESEM) (Neon 40, Zeiss, 
Germany) operating at 5 kV was used to observe the internal microstructure of the 
CPFs. Prior to observation samples were AuV-sputter coated (K950X, Emitech, US). 
The specific surface area (SSA) of Doxy-containing CPFs was evaluated by Nitrogen 
adsorption using the Brunauer–Emmett–Teller (BET) theory using an ASAP 2020 
(Micromeritics, USA). 
The skeletal density of non-foamed CPCs with varying amounts of Doxy was 
measured by helium pycnometry (AccuPyc 1330, Micromeritics, USA). Density was 
evaluated by mercury immersion to obtain the volume of the sample and direct 
weighting. The densities of both CPCs, i.e. CPFs without the foaming step, and CPFs, 
with the same compositions were determined and allowed the calculation of the total 
porosity, and the amount of porosity introduced by foaming, herein called total 
macroporosity [25]. 
Mercury Intrusion Porosimetry (MIP, AutoPore IV, Micromeritics, USA) was 
performed to determine the pore entrance size distribution (PESD) within the materials. 
Moreover, the open macroporosity was determined as the integral of the MIP PESD for 
pore diameters greater than 10µm. Four cylindrical samples of 6 mm diameter and 12 
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mm height were introduced in the sample holder for the measurement, and a single 
measurement was performed for each composition.  
A v/tome/X (Phoenix, USA) micro-computed tomography scanner was used to 
evaluate the 3D morphology of CPFs. The scanner was operated to obtain a voxel size 
of around 10 µm3. The samples were cylinders of 6 mm diameter and 12 mm height. 
The 3D volume was then reconstructed using ImageJ (U. S. National Institutes of 
Health, USA). 
2.4. Antibiotic release evaluation 
CPFs were prepared and cast manually into cylindrical molds of 8 mm diameter 
and 4 mm height with only one open side to allow contact with the release medium and 
were then kept for 1 h in 100 % relative humidity to allow them to have sufficient 
cohesion. Two controls were prepared: a 0D-CPF and a control CPC which was 
prepared using the same composition and protocol as 2D-CPF but removing the 
foaming step. A Dissolution Tester (Pharma Alliance, USA) was used to evaluate the 
release following an adaptation of the USP Pharmacopeia Paddle Dissolution Test. Each 
sample was put in an individual amber glass filled with 150 mL of Phosphate Buffer 
Saline (PBS). Stirring conditions were set to 150 rpm and temperature to 37 ºC 
according to the current United States Pharmacopeia (USP) chapter <711> Dissolution 
[26]. Sampling consisted of the extraction of 1 mL aliquot and its replacement by 1 mL 
of fresh PBS at determined times up to 100 h. Four replicates of each kind of sample 
were evaluated.  
Doxy was quantified by UV-VIS spectrophotometry using a microplate reader 
(Infinite M200 Pro Microplate Reader, TECAN, Switzerland), at the maximum 
wavelength of Doxy λ = 351 nm. This measurement was then corrected for evaporation, 
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sampling effect and degradation of the antibiotic as in previous studies [8] using 
MatLab software (The Mathworks Inc., USA). The percentage released was plotted as a 
function of time. Modeling was performed using the Korsmeyer Peppas (KP) model. 
The variable fitted is the quantity released Mt, normalised by the maximum quantity 
released M∞ (Eq. 1). 
       ⁄  . 
	
    Equation 1 
where k is a constant that accounts for structural parameters of the material and 
characteristics of the active principle such as the effective coefficient of diffusion. The 
exponent n allows the identification of the mechanism controlling the release. 
Specifically, for a given geometry of the sample it allows discerning between a release 
controlled by Fickian diffusion, swelling/case II transport or an intermediate situation. 
The KP model is applicable only up to 60 % of the quantity released. None of the CPFs 
reached that value after 100 h. Thus, the fitting was performed considering that M∞ is 
unknown and that only the constant k is affected by the normalisation by M∞. The 
exponent n describes the shape of the curve and is not affected by the normalisation. 
The quantity released as a function of time was thus fitted with the KP equation and 
both the value of the exponent n and the correlation coefficient R2 were reported. 
2.5. Antibacterial activity 
The antibacterial activity of the materials was tested against two bacterial strains 
commonly found in osteoarticular as well as in nosocomial infections: Staphylococcus 
Aureus (S.Aureus) and Escherichia Coli (E.Coli) from the Culture Collection of the 
University of Göteborg, Sweden. The culture media was prepared by dissolving 3.7 
wt% of Brain Heart Infusion broth (BHI, Scharlau, Spain) in distilled water, which was 
sterilised by autoclaving. To determine the antibacterial activity of the materials, the 
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agar diffusion test was used. This test allows determining the effectiveness of a 
diffusible anti-microbial agent, in our case an antibiotic, to inhibit the bacterial growth. 
The test was performed by plating 107 colony forming units (CFU) on agar plates, 
previously prepared with the appropriate culture media containing 1.5 % bacteriological 
agar (Scharlau, Spain). Three equidistant holes of 9.5 mm in diameter by 3 mm depth 
with a total volume of 0.23 cm3 were performed in each agar plate. The freshly prepared 
CPFs were then injected in the hole taking special care to ensure lateral contact with the 
agar media. After incubation at 37 ºC overnight, the diameter of inhibition for each 
sample was measured using images of the plates taken with a digital camera. The 
inhibition zone was calculated from the diameter of the inhibition zone (Øiz) and the 
diameter of the material (Øm), according to Eq. 2 [27]. Three replicates of each 
formulation were used (n = 3). 

		  Ø  Ø/2   Equation 2 
2.6. Statistics 
Statistical differences were determined using one-way ANOVA with Tukey’s post-hoc 
tests using Minitab 16 software (Minitab, Inc., USA). Statistical significance was 
considered when p < 0.05. Data are presented as mean ± standard deviation. 
 
3. Results 
3.1. Material characterisation 
To evaluate the potential influence of Doxy on the preparation process and on 
the properties of the CPFs, the effect of antibiotic addition on the surface tension of the 
liquid phase was measured. Various solutions were prepared containing 1 wt% of 
Tween 80 and different concentrations of Doxy. The surface tension of pure water, 
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72.37 ± 0.02 mN/m and Tween 80 (1 wt%), 39.66 ± 0.34 mN/m was also recorded as 
control (Fig. 2). Although increasing Doxy concentrations significantly decreased 
surface tension with a total difference of 8 % from 25 to 100 mg/mL solutions, the 
differences were small compared to the large reduction induced by the surfactant.  
The plastic limit of non-foamed CPCs, defined as “the minimum amount of 
liquid that had to be added to a powder to form a paste” [23] was evaluated as a function 
of the amount of Doxy added to the solid phase (Fig. 3), as an indication of the ease of 
producing a paste at different Doxy concentrations. No statistically significant 
differences (p > 0.05) were observed between the plastic limit of pastes with no or low 
quantities of Doxy i.e. from 0D-CPF to 2D-CPF. However, the plastic limit increased 
significantly for 3D-CPF and 4D-CPF, p=0.03 and 0.05 respectively, so these 
formulations required more water to form a paste. Also, at constant liquid-to-powder 
ratio a system containing more Doxy appeared “drier” than a mixture containing less 
Doxy. 
All Doxy-containing formulations presented excellent cohesion i.e. level 4. Even 
injecting the paste readily after preparation, the foams kept the integrity, and were intact 
after 24 h immersion in water, without any particle released to the surrounding medium. 
Only in the 0D-CPF a small fraction of particles detached from the paste, although the 
foam did not disintegrate, and the paste was able to consolidate after 24 h, thus recorded 
as level 3. 
Figure 4 shows the injectability as well as the injection force required to extrude 
the CPF pastes. It can be observed that all Doxy-containing foams were injectable i.e. 
more than 80 % of the foamed paste could be extruded, with relatively low injection 
force values, between 25 and 30 N.  
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Calcium deficient hydroxyapatite (CDHA) was obtained as a result of the 
hydrolysis of α-TCP in all CPFs, in agreement with previous studies [4, 11]. The 
addition of Doxy resulted in a slight increase of unreacted α-TCP, from around 1 % for 
0-CPF to 4-7 % for 1,2,3 and 4D-CPF, but no clear dose-dependency was observed 
(Supplementary information, Fig. S1). The SSA of CPFs increased from 20 to 30 m2/g 
with increasing amounts of Doxy (Table 2), until a plateau value of approximately 31 
m2/g for loadings above 1.77 wt%, corresponding to 2D-CPF.  
The morphology of the foams obtained with different amounts of Doxy is shown 
in Fig. 5. The macrostructure of the CPFs was clearly dependent on the amount of Doxy 
loaded. At higher Doxy concentrations, the foam-like structure of the materials was 
damaged and led to its collapse in some areas, which appeared less porous in the case of 
the 3D-CPFs and 4D-CPFs.  
More detailed SEM images of the fracture surfaces of the 0D-CPF and 2D-CPF 
samples are shown in Fig. 6, both at low and high magnifications. Macropores were 
spherical and interconnections between adjacent pores were observed in the walls of 
most of them. Imaging of the pore walls revealed that 0D-CPF presented separate 
spherical aggregates of needle-like crystals resulting from the dissolution of individual 
α-TCP particles and precipitation of calcium-deficient hydroxyapatite crystals. The 2D-
CPF showed the same basic structure of crystalline aggregates but with the particularity 
that on the pore walls the entangled matrix of plate-like crystals had grown flat possibly 
due to combined presence of Doxy and Tween at the interface with air. 
The skeletal density of non-foamed CPCs determined by helium pycnometry 
was not affected by the addition Doxy and was 2.75 ± 0.02 g.cm-3. The total porosity 
and total macroporosity of the different CPFs measured by mercury immersion, together 
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with the interconnected porosity and interconnected macroporosity recorded by MIP are 
shown in Fig. 7a. The pore entrance size distribution (PESD) in the foams containing 
different amounts of antibiotic is displayed in Fig. 7b. Total porosity showed minor 
variations, from 71.98 ± 4.94 % in 0D-CPF to 65.99 ± 7.39 % in 4D-CPF. The addition 
of antibiotic to the CPFs led to a gradual reduction of the total macroporosity from 50.2 
± 4.9 % for an antibiotic-free 0D-CPF to 22.8 ± 7.4 % for a 4D-CPF. Focusing on the 
doxy-containing CPFs, the total macroporosity decreased linearly with increasing 
amount of Doxy at a rate of approximately 10 % every 25 mg of Doxy. Moreover, more 
than 2/3 of the total macroporosity was interconnected except for 4D-CPF, where the 
percentage of interconnected macropores was lower. 
The PESD was bimodal in all formulations containing Doxy, with the peaks 
centred around 50 nm and 100 µm, while the 0D-CPF showed an additional peak in the 
micrometer range, at 3 µm. The diameter of open macropores i.e. those greater than 10 
µm as previously defined, slightly decreased with increasing amount of antibiotic. The 
intensity and position of the peak centred at 50 nm of all antibiotic-containing CPFs 
slightly increased with increasing amount of Doxy, while the pristine CPF showed 
bigger pore entries with a mode diameter around 100 nm. The images obtained by 
micro-computed tomography for 0D-CPF and 2D-CPF shown in Fig. 8 provide an 
outlook of the morphology and macrostructure of these materials. The 2D-CPF showed 
smaller and less-defined macropores compared to the 0D-CPF. 
3.2. Antibiotic release profile 
The Doxy release kinetics was evaluated for all CPF formulations. The 
percentage released is represented as a function of time (Fig. 9a) for all CPFs and for a 
2D-CPC, the non-foamed counterpart of the 2D-CPF. The initial quantity loaded, the 
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final quantity released and the corresponding percentage released after 5 days are 
reported in Fig. 9b, while the relationship between final percentage released and 
interconnected macroporosity is represented in Fig. 9c. CPFs released a decreasing drug 
percentage with increasing initial amount of Doxy (Fig. 9 a and b), from 54.88 ± 5.82 % 
to 19.58 ± 2.59 % from 1D-CPF to 4D-CPF,  respectively. In none of the cases was a 
burst release observed; instead, the rate of release slowly decreased with time (Fig. 9a). 
The different formulations displayed potential for longer release, as the stationary state 
was not reached in the timeframe of this study. A maximum of 1 mg was released by 
2D-CPFs in 5 days. The percentage released was found to be proportional to the 
macroporosity of the CPF (Fig. 9c), fitting linearly with a slope of 1.23 which suggested 
that interconnected macroporosity had a major influence on the percentage released. 
The KP model was applied to interpret the release kinetics of the CPFs. The fitting 
parameters are reported in Table 3. 
3.3. Antibacterial activity 
The antibacterial activity of the materials against S. Aureus and E. Coli is shown 
in Fig. 10a. All antibiotic-containing materials displayed antibacterial properties, while 
the pristine, 0D-CPF used as control showed no bacterial inhibition. Concerning E. 
Coli, the 2D-CPC, 1D-CPF and 2D-CPF presented similar inhibition zone sizes. The 
3D-CPF and 4D-CPF showed a higher value (p < 0.05). The diffusion test with the S. 
Aureus strain did not reveal statistically significant differences between materials. When 
comparing the CPFs with their non-foamed counterpart 2D-CPC, no differences in the 
inhibition zone size were recorded. To further understand this result, the Doxy loading 
and the apparent density as determined by MIP of each material were used to calculate 
the absolute amount of antibiotic in the agar hole at the beginning of the test, reported in 
Table 4.  
  
16 
The absolute amount of Doxy present in the material at the beginning of the test 
was used to normalise the inhibition zone size (Fig. 10b). After normalisation, it was 
clear that macroporous matrices were more efficient than dense matrices regardless of 
the amount of active principle loaded. The bacteriostatic effect of the materials tested 
decreased with macroporosity. 
4. Discussion 
The CPFs developed in this work combine a number of major advantages as 
bone grafting materials able to locally deliver antibiotic. Together with the injectability, 
self-setting ability, and intrinsic nano/microporosity characteristic of CPCs, they exhibit 
a significant interconnected macroporosity that is known to be crucial for cell 
colonisation, angiogenesis and, in general, for the events leading to bone regeneration 
[7, 11, 28]. In this work we demonstrated that the interconnected macroporosity of the 
injectable CPFs designed had also a significant impact in the control of the drug release 
kinetics of Doxycycline hyclate. 
To generate the macroporous structures, a 1 wt% Tween80 solution was used as 
foaming agent. Since the surface tension changes produced by antibiotic on this solution 
were minor (Fig. 2), they were not expected to significantly affect foamability. In 
contrast, a clear effect on the plastic limit was registered upon the addition of high 
concentrations of Doxy (Fig. 3), suggesting that Doxy absorbed water, resulting in a 
drying effect on the unfoamed paste. An increased shear stress was thus needed to mix 
the powder phase with the foamed liquid phase, which can explain the partial collapse 
of the foamed template at high contents of Doxy, as observed in the optical microscope 
images (Fig. 5) and corroborated by the macroporosity results (Fig. 7a). Anyhow, this 
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was not detrimental to their injectability which was maintained in all formulations, and 
is an essential requirement to ensure their clinical applicability. 
The general outlook to the material macrostructure obtained by micro computed 
tomography reconstructions (Fig. 8) confirmed that the addition of Doxy reduced both 
the size of the macropores and the number of their interconnections. 
The addition of Doxy did not prevent the foam’s setting reaction 
(Supplementary material Fig. S1), where the dissolution of α-TCP was followed by the 
precipitation of CDHA [4, 11]: 
Ca3(PO4)2 (s) + H2O(l)  →  Ca9(HPO4)(PO4)(OH)(s) 
However, the presence of the antibiotic was related to an increase of SSA (Table 
2) which was associated to its effect on the microstructure of the CDHA crystals 
formed. In fact, it was suggested in a previous study [8] that, due to its Ca-chelating 
ability, Doxy can act in this kind of systems as a nucleating agent, promoting the 
formation of smaller crystals and leading to a more homogeneous microstructure, as 
shown in Fig. 6. This is in agreement also with the disappearance -in the MIP diagram 
of the Doxy-containing samples (Fig. 7b) of the peak around 3-5 µm detected in the 
pristine foams. 
The introduction of macroporosity in the CPCs clearly modified the drug release 
profile, as observed when comparing the 2D-CPF with its non-foamed counterpart 2D-
CPC. The percentage released from CPFs was significantly higher in all cases compared 
to the 2D-CPC (Fig. 9b). However, the interdependence between Doxy concentration 
and macroporosity introduced additional complexity in the system. The addition of 
Doxy led to a progressive loss of total porosity as well as of interconnected 
macroporosity (Fig. 7a) and a reduction in the entrance pore size of the macropores 
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(Fig. 7b). This was shown to be highly relevant for their drug release properties; 
Different release kinetics were observed in the CPFs depending on the amount of Doxy 
loaded; the rate of percentage released decreased with increasing Doxy concentrations, 
which can be related to the lower volume of macropores and their smaller size (Fig. 8 
and 7b). Although CPFs were more porous than CPCs, and thus a lower amount of 
Doxy was present in the same volume, CPFs released a higher absolute amount of Doxy 
after 5 days, with a maximum of 1 mg for the 2D-CPF.  
Besides, the uniform distribution of the drug in the matrix of all formulations 
studied was revealed by the progressive release observed i.e. no initial burst (Fig. 9a). In 
general, the availability of active principles to the bone is limited and slow, as compared 
to soft tissues or other organs for instance. The on site direct bioavailability of the active 
principle, in our case Doxycycline hyclate, maximized the efficiency of the treatment. 
The extended drug release profiles obtained with the present CPFs are highly desirable 
in controlled drug delivery matrices, as a reproducible rate and prolonged delivery are 
obtained, and allow lower amount of drugs to be used [29].  
For the treatment of infection, ideally a high concentration of antibiotics is 
needed in the first 1–2 days and thereafter a prolonged release of a lower concentration 
should be maintained for another 4 weeks [30]. Although the lack of burst release may 
be a disadvantage when dealing with prophylactic therapy of infections, the CPFs 
designed here can be envisaged in this case as a complementary therapy to an initial 
parenteral or oral antibiotic administration, delivering Doxy on-site for the continuation 
of the treatment, and thus improving patient compliance. For instance, the 3D-CPF and 
4D-CPF showed potential for release during 3 or 4 weeks, suitable for bone infection 
treatment. 
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The close relationship between different structural properties such as SSA, 
macroporosity, interconnected macroporosity, porosity and interconnected porosity was 
put forward by their direct correlation with the percentage released by the CPFs using a 
linear fit (not shown). The quality of fit obtained, estimated through the correlation 
coefficient (R2), was 0.842, 0.957, 0.918, 0.931 and 0.910 for SSA, macroporosity, 
interconnected macroporosity, porosity and interconnected porosity, respectively. The 
good correlation between the amount of macroporosity and the percentage of Doxy 
released (Fig. 9c) confirmed that macroporosity plays a key role in the drug release 
phenomena by enhancing fluid exchange and increasing the accessible surface, thus 
facilitating drug delivery and availability. 
The fitting of the release profiles led to n values comprised between 0.50 and 
1.00 (Table 3), which for a planar geometry corresponds to a non-Fickian diffusional 
release [31, 32]. It is known that a non-Fickian transport may be due to structural 
changes, temperature, saturation of the release media, etc. As the experiments were 
performed in sink conditions, and following standards [26], this non-Fickian behavior 
could be attributed to the self-setting nature of CPFs. Their microstructure evolving 
over time is responsible for the anomalous diffusion, as shown in previous works [8].  
All antibiotic-containing CPFs showed bacteriostatic effect on both E. Coli and 
S. Aureus (Fig. 10a) in an agar diffusion test. E. Coli was selected as the most 
commonly found bacteria in nosocomial infections together with S. Aureus, which is 
also very often responsible of osteo-articular infections. The results obtained were 
function of both the matrix ability to release the active principle and the initial amount 
of active principle present in the material. In this kind of test where solid-solid contact 
i.e. agar – material, is crucial for the diffusion of the antibiotic, the architecture of the 
material plays an important role: while the unfoamed CPC has an optimum contact with 
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the agar, the macroporosity of the CPF revert in few contact points with the agar, 
hampering the diffusion of the material. Additionally, no direct correlation can be 
sought between the release in liquid media in sink conditions with free diffusivity and 
the release established in agar. Nevertheless, this test has shown the antibacterial 
efficiency of the material.  
As the same volume of material was placed in the agar, for the same wt% of 
Doxy in the material the absolute quantity of antibiotic present is lower when the matrix 
used is more porous. The inhibition zone size was thus normalised by the absolute 
quantity of Doxy present in the material. The results proved that, even in the static 
conditions of this test and the lower amount of contact points with the agar, the 
interconnected macroporous structure exhibited by the CPFs was more efficient in terms 
of ensuring antibiotic availability than their microporous counterpart, namely CPCs 
(Fig. 10b, Table 4). 
Different antibiotic release profiles are reported in the literature for calcium phosphate 
cements: from slow releasing dosage forms [8, 33–36] to very fast burst release of the 
antibiotic [37, 38]. Although some approaches successfully prevented the risk of 
antibiotic resistance by releasing almost all the drug loaded [39], the dosage forms did 
not present an adequate macrostructure to enhance bone ingrowth. The calcium 
phosphate foams presented in this study exhibit a progressive release profile up to 1 mg 
in 5 days, corresponding to 55% of the quantity loaded in 2D-CPC, with potential for 
complete release and a simultaneous interconnected macroporosity of around 25 % (Fig. 
9c) that is expected to enhance, in addition, tissue colonisation.  
It has been put forward that tetracyclines inhibit bone resorption through different 
mechanisms such as decreased osteoclast activity, so incomplete release of the drug 
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could be detrimental [40]. In the case of CPCs, it has been commonly observed that 100 
% release is not reached, regardless of the active principle used [6]. This aspect, which 
can be very significant in the case of CPCs, is expected to be minimized thanks to the 
macroporous structure of the foams. In fact, it has been shown that the presence of an 
interconnected network of macropores in the material enhances its resorption rate [41]. 
Thus, in case there was some unreleased residual Doxy in the material, the low 
quantities employed in the loading of the CPFs, and their macroporosity enhancing fluid 
circulation and resorption rate would minimize the inhibiting effects of Doxy on 
osteoclasts, in addition to potential bacterial resistance.  
 
5. Conclusion 
Calcium Phosphate Foams (CPFs) were shown to be attractive drug delivery 
systems for osteo-articular applications as compared to Calcium Phosphate Cements 
(CPCs), since they overcome several of their limitations. First, CPFs exhibited an 
interconnected macroporous structure while maintaining injectability, cohesion and self-
setting ability, thus providing a template for bone ingrowth. Second, CPFs were more 
efficient as drug release systems, since less active principle was loaded and higher 
percentages and absolute amounts were released after 5 days, with potential for longer 
release. The therapeutic effect is expected to increase, while the risk of generating 
antibiotic-resistant bacteria due to the antibiotic still present in the matrix is reduced. 
Finally, the control of both macrostructure and release profile allowed designing 
versatile and efficient drug delivery systems that can be adapted to different 
applications. While CPFs are limited to non-load bearing applications, the combination 
of a prophylactic antibiotic release with a biomimetic composition and structure makes 
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them an attractive solution to today’s challenges in the fields of orthopaedics, spine and 
maxillofacial bone regeneration. 
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Figure Captions 
 
Figure 1: Structural formula of Doxycycline hyclate. 
Figure 2: Surface tension measurements dissolutions of Tween (1 wt%) containing 
different amounts of Doxy (25, 50, 75 and 100 mg/mL) equivalent to the 1D-CPF, 2D-
CPF, 3D-CPF and 4D-CPF respectively. Dashed lines indicate the surface tension of 
water and of a 1 %Tween 80 solution (0D-CPF). (n=10). 
Figure 3: Plastic limit of non-foamed materials for different Doxy loadings. *, ** 
indicate statistically significant groups (p<0.05). 
Figure 4: Injection force (N) and injectability (%) of pristine and antibiotic-loaded 
calcium phosphate foams. • and + represent statistically significant differences (p<0.05) 
between compositions with the same symbol. 
Figure 5: Optical microscope images of the CPFs obtained with different concentrations 
of Doxy, from left to right: 0D-CPF, 1D-CPF, 2D-CPF, 3D-CPF and 4D-CPF. 
Figure 6: FESEM images of the fracture surface of CPFs with detail of the macropore 
walls of a 0D-CPF (left) and a 2D-CPF (right) at different magnifications: 50x, 2500x 
and 10000x (from top to bottom). 
Figure 7: Porosity characterisation of CPFs containing different amounts of Doxy: (a) 
Total porosity and total macroporosity as measured by immersion in Hg (n=12); 
interconnected porosity and interconnected macroporosity as determined by MIP (n=4); 
and (b) MIP pore entry size distribution (n=4). 
Figure 8: 3D reconstruction of a micro-computed tomography scan of a 5x5x5 mm3 
cubic volume a 0D-CPF (a) and 2D-CPF (b) 
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Figure 9: (a) Release curves of CPFs containing different amounts of Doxy. A 2D-CPC 
is included for comparison; (b) Initial quantity loaded, final quantity released and final 
percentage released (100 h); (c) Final percentage released as a function of the  
macroporosity of the CPFs and CPC. 
Figure 10: (a) Antibacterial activity against Escherichia Coli and Staphylococcus 
Aureus of CPFs containing different amounts of Doxy and a non-foamed 50-CPC 
counterpart. (b) Normalisation of the antibacterial activity by the absolute amount of 
antibiotic in the materials. For E. Coli, *, **, *** and **** indicate statistically 
significant differences (p < 0.05). For S. Aureus, , ,  and  indicate statistically 
significant differences (p < 0.05). 
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Tables 
 
Table 1: Nomenclature of the different CPFs, amounts of water, calcium phosphate 
(CaP) powder and antibiotic, and corresponding weight percentage of antibiotic with 
respect to the total weight of the CPFs (Cdoxy). 
 
Nomenclature Liquid phase (mL) 
CaP powder  
(g) Doxy (mg) Cdoxy (wt%) 
0D-CPF 1 1.820 0 0 
1D-CPF 1 1.820 25 0.88 
2D-CPF 1 1.820 50 1.76 
3D-CPF 1 1.820 75 2.64 
4D-CPF 1 1.820 100 3.52 
 
 
 
 
 
Table 2:  Specific surface area (SSA, BET theory) of Doxy-containing CPFs. 
Composition SSA (m2/g) ± SD 
0D-CPF 20.25 ± 0.03 
1D-CPF 23.47 ± 0.12 
2D-CPF 30.47 ± 0.18 
3D-CPF 31.77 ± 0.20 
4D-CPF 30.94 ± 0.19 
 
 
  
31 
Table 3: Fitted parameters of the Korsmeyer Peppas model, type of limiting transport 
mechanism. 
Formulation n R2 Transport Mechanism 
1D-CPF 0.63 0.9866 Non-fickian diffusion 
2D-CPF 0.60 0.9982 Non-fickian diffusion 
3D-CPF 0.57 0.9953 Non-fickian diffusion 
4D-CPF 0.65 0.9961 Non-fickian diffusion 
 
 
 
 
Table 4: Calculated parameters for antibiotic-loaded CPCs and CPFs employed in the 
antibacterial tests: concentration of Doxy, apparent density, and absolute amount of 
Doxy in the agar hole (0.23 cm3). 
 
Material Cdoxy (wt%) Apparent density (g/cm3) 
 Qdoxy (mg) in the 
agar defect 
2D-CPC 1.76 1.290 5.22±0.69 
1D-CPF 0.88 0.748 1.51±0.71 
2D-CPF 1.76 0.808 3.27±0.67 
3D-CPF 2.64 0.930 5.01±1.41 
4D-CPF 3.52 0.932 7.55±2.44 
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